SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001140361-24-042965
Filing Date
2024-10-07
Accepted
2024-10-07 16:05:23
Documents
4
Period of Report
2024-11-14

Document Format Files

Seq Description Document Type Size
1 PRE 14A ny20036093x1_pre14a.htm PRE 14A 147015
2 logo_oruka.jpg GRAPHIC 37750
3 ny20036093x1_pc01.jpg GRAPHIC 549872
4 ny20036093x1_pc02.jpg GRAPHIC 568514
  Complete submission text file 0001140361-24-042965.txt   1739827
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 000-22873 | Film No.: 241357837
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)